Further evidence was provided by Bopp and coworkers, who demonstrated that blocking phosphodiesterase 4 (PDE4), a cAMP-degrading enzyme, in an allergic asthma mouse model led to increased cAMP levels and reduced airway hyperresponsiveness and inflammation (31). This evidence concerns the gene PDE4A and allergic asthma.